To sum up, the RCC-specific aberrant methylation of TFAP2B, TAC1, PCDH8, ZNF677, and FLRT2 is detectable in urine from patients with SRM and is potentially suitable for non-invasive early detection and follow-up of the disease. Here, TFAP2B is linked to renal cell carcinoma.